🎉 M&A multiples are live!
Check it out!

Acurx Pharmaceuticals Valuation Multiples

Discover revenue and EBITDA valuation multiples for Acurx Pharmaceuticals and similar public comparables like Galapagos, Benevolent AI, and Vivoryon Therapeutics.

Acurx Pharmaceuticals Overview

About Acurx Pharmaceuticals

Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company’s segment consists of the development of clinical and preclinical product candidates for the development of the Company’s proprietary new therapies.


Founded

2017

HQ

United States of America
Employees

4

Website

acurxpharma.com

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

$4.7M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Acurx Pharmaceuticals Financials

Acurx Pharmaceuticals has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Acurx Pharmaceuticals achieved revenue of n/a and an EBITDA of -$14.1M.

Acurx Pharmaceuticals expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Acurx Pharmaceuticals valuation multiples based on analyst estimates

Acurx Pharmaceuticals P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$14.6M -$14.1M XXX XXX XXX
EBITDA Margin -Infinity% -Infinity% XXX XXX XXX
Net Profit -$12.1M -$14.6M XXX XXX XXX
Net Margin -Infinity% -Infinity% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Acurx Pharmaceuticals Stock Performance

As of April 15, 2025, Acurx Pharmaceuticals's stock price is $0.

Acurx Pharmaceuticals has current market cap of $8.4M, and EV of $4.7M.

See Acurx Pharmaceuticals trading valuation data

Acurx Pharmaceuticals Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$4.7M $8.4M XXX XXX XXX XXX $-0.84

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Acurx Pharmaceuticals Valuation Multiples

As of April 15, 2025, Acurx Pharmaceuticals has market cap of $8.4M and EV of $4.7M.

Acurx Pharmaceuticals's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Acurx Pharmaceuticals's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Acurx Pharmaceuticals and 10K+ public comps

Acurx Pharmaceuticals Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $4.7M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA -0.3x XXX XXX XXX
P/E -0.6x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -0.5x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Acurx Pharmaceuticals Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Acurx Pharmaceuticals Valuation Multiples

Acurx Pharmaceuticals's NTM/LTM revenue growth is n/a

Acurx Pharmaceuticals's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $3.5M for the same period.

Over next 12 months, Acurx Pharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Acurx Pharmaceuticals's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Acurx Pharmaceuticals and other 10K+ public comps

Acurx Pharmaceuticals Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth -3% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $3.5M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Acurx Pharmaceuticals Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Acurx Pharmaceuticals M&A and Investment Activity

Acurx Pharmaceuticals acquired  XXX companies to date.

Last acquisition by Acurx Pharmaceuticals was  XXXXXXXX, XXXXX XXXXX XXXXXX . Acurx Pharmaceuticals acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Acurx Pharmaceuticals

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Acurx Pharmaceuticals

When was Acurx Pharmaceuticals founded? Acurx Pharmaceuticals was founded in 2017.
Where is Acurx Pharmaceuticals headquartered? Acurx Pharmaceuticals is headquartered in United States of America.
How many employees does Acurx Pharmaceuticals have? As of today, Acurx Pharmaceuticals has 4 employees.
Who is the CEO of Acurx Pharmaceuticals? Acurx Pharmaceuticals's CEO is Mr. David P. Luci.
Is Acurx Pharmaceuticals publicy listed? Yes, Acurx Pharmaceuticals is a public company listed on NAS.
What is the stock symbol of Acurx Pharmaceuticals? Acurx Pharmaceuticals trades under ACXP ticker.
When did Acurx Pharmaceuticals go public? Acurx Pharmaceuticals went public in 2021.
Who are competitors of Acurx Pharmaceuticals? Similar companies to Acurx Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Acurx Pharmaceuticals? Acurx Pharmaceuticals's current market cap is $8.4M
Is Acurx Pharmaceuticals profitable? Yes, Acurx Pharmaceuticals is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.